2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study. (September 2015) - Hsu, C.; Lee, S.H.; Ejadi, S.; Even, C.; Cohen, R.; Le Tourneau, C.; Mehnert, J.; Algazi, A.; Van Brummelen, E.; Yuan, S.S.; Thanigaimani, P.; Cheng, J.